Most Rural Counties Lack Medicare Methadone Detox Access

Medical detox for opioid use disorder often depends on methadone, but a new study finds that more than 93 percent of rural counties in the United States have no Medicare-enrolled opioid treatment program able to dispense it.

This leaves millions of older adults with limited options for medically supervised care.

Why Medical Detox Access Matters Here

Methadone is one of three FDA-approved medications for opioid use disorder, alongside buprenorphine and naltrexone, and it remains an important option for medical detox and long-term treatment, particularly for people using fentanyl, since it does not trigger precipitated withdrawal the way some other medications can.

Unlike buprenorphine, which any eligible clinician can prescribe in an office setting, methadone can only be dispensed through a federally certified opioid treatment program, making access to a physical facility essential.

Researchers examined the June 2025 Centers for Medicare & Medicaid Services database of Medicare-enrolled opioid treatment programs and found that only 681 of the nation’s counties, about 22 percent, had one at all.

Among urban counties, 46 percent had an enrolled program. Among rural counties, only 6.9 percent did, and most of those were in larger micropolitan areas rather than the most remote, noncore rural counties.

The Scale of the Access Gap

The study estimated that about 9.3 million Medicare enrollees and 31.1 million adults overall live in rural counties without a single Medicare-enrolled methadone provider nearby.

Access also varied by region, with the West North Central and West South Central census divisions showing the lowest availability.

Counties with lower rates of post-secondary education and employment also had fewer enrolled programs, though counties classified as facing persistent poverty actually had a higher supply than other counties.

Medicare began covering opioid treatment program services in 2020 under the SUPPORT Act, and the number of enrolled programs has grown since then.

Even so, only a small share of Medicare enrollees with opioid use disorder receive methadone treatment at all, and roughly 1.1 million Medicare enrollees carry an opioid use disorder diagnosis.

Why Distance to Detox and Treatment Is a Safety Issue

For opioid treatment programs, distance is not just an inconvenience. Methadone dosing typically requires frequent, sometimes daily, in-person visits, especially early in treatment, and prior research cited in the study found that longer travel times to a program are linked to lower odds of accessing methadone at all and to a higher chance of missing doses once in treatment.

Missed doses can mean a return of withdrawal symptoms and a higher relapse risk during an already vulnerable period.

The researchers pointed to several possible ways to close the gap, including primary care prescribing paired with pharmacy dispensing and continued use of federal flexibilities like mobile medication units and expanded telehealth options for opioid treatment programs, which were introduced to help rural areas.

Finding Medical Detox in Rural Communities

Anyone in a rural area who is not sure what opioid use disorder treatment is realistically available nearby should ask directly about medication options, including whether a local provider offers buprenorphine, whether the nearest methadone program accepts new patients, and whether telehealth or mobile treatment options exist in the area.

Detox.com can help connect people with medically supervised detox and MAT providers, including options for people in rural communities who may need to look beyond their immediate county. Call 800-996-6135(Sponsored) to speak with a treatment advisor today.